Chen HZ - Search Results

1

Liposomes-enabled cancer chemoimmunotherapy.

Zhang L, Shi J, Zhu MH, Huang Y, Lu Q, Sun P, Chen HZ, Lai X, Fang C. Zhang L, et al. Among authors: chen hz. Biomaterials. 2025 Feb;313:122801. doi: 10.1016/j.biomaterials.2024.122801. Epub 2024 Sep 3. Biomaterials. 2025. PMID: 39236630 Review.

2

Tumor Metabolism-Rewriting Nanomedicines for Cancer Immunotherapy.

Dong X, Xia S, Du S, Zhu MH, Lai X, Yao SQ, Chen HZ, Fang C. Dong X, et al. Among authors: chen hz. ACS Cent Sci. 2023 Sep 22;9(10):1864-1893. doi: 10.1021/acscentsci.3c00702. eCollection 2023 Oct 25. ACS Cent Sci. 2023. PMID: 37901179 Free PMC article. Review.

3

Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.

Zhang X, Wu Y, Lin J, Lu S, Lu X, Cheng A, Chen H, Zhang W, Luan X. Zhang X, et al. Acta Pharm Sin B. 2024 Sep;14(9):3818-3833. doi: 10.1016/j.apsb.2024.05.013. Epub 2024 May 13. Acta Pharm Sin B. 2024. PMID: 39309492 Free PMC article. Review.

4

Tachyplesin I and its derivatives: A pharmaco-chemical perspective on their antimicrobial and antitumor potential.

Lu S, Lin J, Jin J, Zhang L, Guan Y, Chen H, Wu Y, Zhang W, Luan X. Lu S, et al. Expert Opin Drug Discov. 2022 Dec;17(12):1407-1423. doi: 10.1080/17460441.2023.2157402. Expert Opin Drug Discov. 2022. PMID: 36503335 Review.

5

Targeted Protein Degradation Technology and Nanomedicine: Powerful Allies against Cancer.

Lin JY, Liu HJ, Wu Y, Jin JM, Zhou YD, Zhang H, Nagle DG, Chen HZ, Zhang WD, Luan X. Lin JY, et al. Among authors: chen hz. Small. 2023 May;19(18):e2207778. doi: 10.1002/smll.202207778. Epub 2023 Jan 24. Small. 2023. PMID: 36693784 Review.

6

Promising natural products targeting protein tyrosine phosphatase SHP2 for cancer therapy.

Lu J, Yu D, Li H, Qin P, Chen H, Chen L. Lu J, et al. Phytother Res. 2024 Apr 1. doi: 10.1002/ptr.8185. Online ahead of print. Phytother Res. 2024. PMID: 38558278 Review.

7

Decoding β-catenin associated protein-protein interactions: Emerging cancer therapeutic opportunities.

Yan Y, Gong Y, Liang X, Xiong Q, Lin J, Wu Y, Zhang L, Chen H, Jin J, Luan X. Yan Y, et al. Biochim Biophys Acta Rev Cancer. 2024 Dec 4;1880(1):189232. doi: 10.1016/j.bbcan.2024.189232. Online ahead of print. Biochim Biophys Acta Rev Cancer. 2024. PMID: 39643250 Review.

8

Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer.

Jin J, Wu Y, Zhao Z, Wu Y, Zhou YD, Liu S, Sun Q, Yang G, Lin J, Nagle DG, Qin J, Zhang Z, Chen HZ, Zhang W, Sun S, Luan X. Jin J, et al. Among authors: chen hz. JCI Insight. 2022 Nov 22;7(22):e160606. doi: 10.1172/jci.insight.160606. JCI Insight. 2022. PMID: 36509291 Free PMC article.

9

TRIM4 enhances small-molecule-induced neddylated-degradation of CORO1A for triple negative breast cancer therapy.

Gu WJ, Liu XX, Shen YW, Gong YT, Chen YL, Lin J, Lu D, Zhang LJ, Chen HZ, Jin Y, Zhan ZJ, Zhang WD, Jin JM, Luan X. Gu WJ, et al. Among authors: chen hz. Theranostics. 2024 Oct 21;14(18):7023-7041. doi: 10.7150/thno.97662. eCollection 2024. Theranostics. 2024. PMID: 39629122 Free PMC article.

10

Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells.

Wang M, Xiang Y, Wang R, Zhang L, Zhang H, Chen H, Luan X, Chen L. Wang M, et al. Molecules. 2022 Nov 11;27(22):7774. doi: 10.3390/molecules27227774. Molecules. 2022. PMID: 36431875 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

803 results

Search Page

Filters